Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Research & Development (2016 - 2025)

Historic Research & Development for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $7.4 million.

  • Northwest Biotherapeutics' Research & Development fell 836.41% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 608.13%. This contributed to the annual value of $34.9 million for FY2024, which is 2581.32% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Research & Development stood at $7.4 million for Q3 2025, which was down 836.41% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Research & Development registered a high of $13.6 million during Q2 2022, and its lowest value of $3.7 million during Q3 2021.
  • In the last 5 years, Northwest Biotherapeutics' Research & Development had a median value of $7.4 million in 2025 and averaged $7.5 million.
  • In the last 5 years, Northwest Biotherapeutics' Research & Development plummeted by 7877.69% in 2021 and then soared by 15032.1% in 2022.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Research & Development stood at $4.2 million in 2021, then soared by 123.41% to $9.4 million in 2022, then fell by 20.3% to $7.5 million in 2023, then surged by 41.17% to $10.5 million in 2024, then fell by 29.2% to $7.4 million in 2025.
  • Its Research & Development stands at $7.4 million for Q3 2025, versus $7.4 million for Q2 2025 and $8.4 million for Q1 2025.